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Introduction
Pharmacogenomics (PGx) technology is advancing rapidly; however, clinical adoption is 
lagging. The Indiana Institute of Personalized Medicine (IIPM) places a strong focus on 
translating PGx research into clinical practice. We will describe what have been found to be 
the key requirements that must be delivered in order to ensure a successful and enduring 
PGx implementation within a large healthcare system.
Over the past 5 years, a technological revolution of new devices has helped to move PGx 
from the research bench to CLIA-approved laboratories while costs of performing PGx 
testing have substantially declined. In 2001 Francis Collins projected that by 2020 PGx 
would be the standard practice for predicting drug responsiveness for many disorders and 
drugs1. A review of published PGx articles demonstrates that clinical research has been 
rapidly expanding2, however as AR Shuldiner, et.al noted “there are a number of substantial 
barriers to the adoption of pharmacogenetic tests into clinical practice”. Two key drivers that 
are holding back the adoption of PGx testing are the lack of expansive, strong clinical 
evidence supporting the routine and prospective use of genetic testing and the void of health 
economic data linking genetic testing with reductions in cost of care. In 2009 the Clinical 
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Pharmacogenetics Implementation Consortium (CPIC) was organized with the first 
guideline published in 2011. Since that time 12 different guidelines and 4 updates have been 
published covering over 26 medications. Despite this extensive and ongoing work there 
remain a significant number of drugs without dosing guidelines that contain FDA issued 
drug-gene “Black Box” warnings3. It is also important to recognize that any change to 
clinical standards of care takes time. The National Institute for Health and Clinical 
Excellence reported that a new clinical procedure can take up to 3 years to become standard 
of care. The time required for clinical translation (research to clinical adoption) often 
exceeds 10 years (range of 10 to 25 years).
The IIPM serves both the Indiana University Health System (over 2.5 million outpatient 
visits and 145,000 admissions annually) and the Eskenazi Health System (a safety-net health 
care system which handles over 1.2 million outpatient visits and 15,000 admissions 
annually). The successful clinical implementation of a PGx program at a large healthcare 
system requires alignment of clinical and administrative stakeholders including: Senior 
executive leadership (CEO/President, Chief Medical Officer, Chief Information Officer, 
Chief Financial Officer and Chief Legal Officer), senior clinical leaders (clinical divisions, 
nursing and pharmacy), pathology, Pharmacy and Therapeutics committee members, patient 
advocates and third party payers. Prior to implementation, committees should be established 
representing these stakeholders. Alignment of common interests and concerns must be 
obtained within and across administrative and clinical stakeholders groups. This alignment 
is crucial if the PGx initiative is to be funded and clinically adopted into the standard of care 
(see figure 1)
The IIPM PGx implementation team worked with key stakeholders and identified critical 
deliverables for each of the groups. After soliciting team members from within the 
institution’s stakeholder domains, strategically important working groups (aligned with 
critical deliverables) were created.
• Clinical Implementation: Comprised of scientists, physicians, nurses and clinical 
pharmacists, this team’s objective was to select which gene-drug pairs would be 
implemented and prepare the clinical direction to be provided. CPIC guidelines on 
gene/drug pairs were used to help select targeted medications and the micro-array 
architecture. Decisions were based on the clinical evidence associated with each 
reportable SNP. Based on the above analysis and a review of new prescriptions 
written within the Eskenazi Health System, 24 targeted medications, 16 genes and 
51 clinically validated allele variants were selected for implementation. The clinical 
implementation team is an evergreen group that continues to meet and review new 
scientific and clinical evidence.
• Laboratory Implementation: This working group included individuals 
experienced in PGx testing and establishing a clinical genetics laboratory. They 
were tasked with identifying and selecting the state of the art equipment required 
for the genetics lab, staffing the laboratory with highly qualified personnel familiar 
with CLIA requirements, laboratory reporting and capital/operating budgets. 
Within the new 1,000 square foot laboratory, the team, after extensive research, 
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selected state of the art micro-array, automated DNA extraction and sample 
handling systems.
• Education and Marketing: Basic education on clinical genetics and the evolving 
science of PGx must be provided to the clinical teams (physicians, advanced 
practice nurses, registered nurses and pharmacists) if a successful implementation 
is to occur. Clinicians who treat outpatients must also clearly understand the tests 
that are available, when to order them and what to do in the event of receiving 
“clinical alerts”. A multifaceted approach was applied. We invited nationally 
known experts to take part in a symposium to address clinical implementation 
challenges. Nurses were provided with internally created on-line education with 
more than 500 completing the course. IIPM staff conducted Grand Rounds focused 
on PGx and held a full day CME program for physicians, nurses and clinical 
pharmacists. In addition to clinical training, lay-education and a public relations 
campaign are also paramount to a program’s success. With today’s direct-to-
consumer advertising about genomic testing, consumers are trying to understand 
the benefits and risks and look to their healthcare professionals for answers. 
Because dissemination of somewhat “uncontrolled” and sometimes misleading 
information creates challenges for the healthcare professional, a successful system-
wide pharmacogenomics program must also address patient and community 
member education4.
• Administration: The administration of a clinical PGx program requires a multi-
disciplinary approach with a specific focus on financial, legal, and regulatory 
issues. Having a team member with strong financial modeling skills is very 
important for project success. An individual with current knowledge of the rapidly 
changing reimbursement and local, state and federal regulatory requirements is 
critical to address the difficult questions frequently asked by the system’s senior 
leadership teams. By using real cost and reimbursement information and system-
based clinical and financial outcomes data, modeling short and long-term cash flow 
and return on investment is often required to justify up-front start-up costs. In 
addition, as part of Indiana University, the IIPM has access to faculty and graduate 
students from the IU Kelly School of Business who assisted in financial modeling 
of the program, thus helping to cost-justify the establishment of the new laboratory 
(space, equipment and staff).
• IT/Workflow: IT solutions must consider clinical workflows and facilitate the 
process for caregivers to order appropriate pharmacogenomic tests. In addition, test 
results must be easy to understand, include clinically validated guidelines, if 
available, and be integrated into the medical record system. By including clinical 
pharmacists, physicians and nurses into the decision making process, the IT/
Workflow team can identify “blind spots” and implementation traps. PGx testing 
must be integrally linked to the EMR (especially for ICD-9 diagnosis coding) and 
to the pharmacy ordering system (linking Rx orders to alerts for pharmacogenomic 
tests). These links are not commonly found in most commercial hospital IT 
systems. Thus, a successful PGx implementation must plan for the cost and time to 
build these links and create the clinician alerts and test results that include the 
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approved therapy guidelines. Within the Eskenazi Healthcare System, the hospital 
information system was created and is maintained by the Regenstrief Institute. The 
Regenstrief Medical Record System compiles laboratory results, orders, 
medications, registration information, nursing assessments, EKGs and other clinical 
data. By working with the Regenstrief team, PGx alerts and result reporting can be 
seamlessly incorporated into current processes and clinical workflow patterns. An 
example of a typical PGx alert is depicted in figure 2.
The IT/Workflow team also provided access to system-wide data on the Rx and test 
frequency along with costs associated with adverse events related to targeted 
medications. These data can then be used for health economic modeling, thus 
balancing the total financial picture associated with the adoption of PGx testing5.
In conclusion, the technology to perform high quality PGx testing is readily available, able 
to be incorporated into a CLIA certified laboratory and is increasingly affordable. However, 
these factors alone do not guarantee a successful implementation of a PGx program. Careful 
planning, data collection and clarity in understanding and addressing stakeholder concerns 
must all be considered. Clinical workflows and system-wide education are essential to 
support an enduring program. A high priority in the early planning stages must be selecting 
PGx tests that are relevant to the patient population. These tests must provide clear, 
evidence-based, well documented direction for therapy changes. In addition, the PGx 
program must be dynamic; ongoing scientific and clinical reviews of the literature must be 
iteratively incorporated into the program. Once implemented, it is also important to continue 
to capture data on medication changes, adverse events and costs associated with targeted 
medication efficacy failures, as these data can be used to validate the cost effectiveness of a 
PGx program.
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Figure 1. 
Alignment required within Clinical and Administrative groups in order to facilitate PGx 
Implementation that is effective and enduring
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Figure 2. 
Is an example of how the Eskenazi EMR PGx Alert may appear when fully implemented
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